Hardware Updates Required to Address Potential Loss of Hemodynamic Support
Abiomed has issued a correction for certain Automated Impella Controllers (AICs) used with the Impella heart pump system after identifying hardware-related issues that could lead to controller startup failures or interruptions in hemodynamic support. The U.S. Food and Drug Administration (FDA) has classified the action as a Class I recall, the agency’s most serious recall category.
Importantly, this action is a device correction rather than a product removal. Hospitals may continue using affected Automated Impella Controllers while coordinating required hardware updates with Abiomed’s field service team.
Affected Device
Product: Impella Controller, Packaged, US
Product Code: 0042-0000-US
UDI-DI: 00813502010022
Affected facilities should review the manufacturer’s notification and verify whether any controller serial numbers in their inventory are included in the correction.
About the Automated Impella Controller
The Automated Impella Controller serves as the primary user interface for the Impella catheter system. The controller manages pump performance, provides alarms and system monitoring, and displays catheter positioning information during patient support.
Why the Correction Was Issued
During a retrospective review of service records, Abiomed identified several hardware-related issues that could potentially impair controller operation.
The identified issues are:
Potential electrostatic discharge interference affecting motor controls due to the proximity of an internal Video Graphics Array (VGA) cable to a Digital Signal Processor (DSP) chipset.
Potential dislodgement of the Compact Flash Memory Card, which could lead to startup failures or data logging issues.
Improper routing of internal fan wiring that could result in cable damage and console boot-up failures.
Capacitor-related issues within the Power Battery Manager assembly that could contribute to pump stop events, purge stop events, or fuse failures.
To address these concerns, Abiomed is implementing hardware modifications including cable retention devices, memory card retainers, improved wire routing controls, and updated Power Battery Manager circuit board assemblies.
Potential Patient Impact
According to the manufacturer, each of the identified hardware issues could result in a failure of the controller to boot properly, sudden interruption of hemodynamic support, and delays associated with exchanging the controller for a replacement device.
Because Impella systems are used to provide temporary mechanical circulatory support for critically ill patients, delays or loss of support may have significant clinical consequences depending on the patient’s hemodynamic status and dependence on the device.
The FDA notes in its recall notice that interruption or delay of hemodynamic support may result in serious injury or death.
As of April 14, Abiomed reported no serious injuries or deaths associated with these issues.
What Facilities Should Do
Abiomed has advised affected customers to continue using existing hospital inventory as needed to maintain continuity of care, work with Abiomed field service representatives to schedule return and modification of affected controllers, notify all personnel responsible for storing, transporting, maintaining, or operating affected devices, and forward the correction notice to any facilities that may have received affected products.
MDP Perspective
While no serious injuries or deaths have been reported, this correction highlights the importance of post-market surveillance and service record analysis in identifying hardware reliability issues before they result in widespread adverse events. The action also serves as a reminder that seemingly minor hardware design issues—including cable routing, component retention, and power management circuitry—can have significant implications when used in life-sustaining medical devices.
Facilities using Impella systems should ensure that affected controllers are identified and scheduled for corrective modification while maintaining adequate operational readiness for patients requiring mechanical circulatory support.
Links
Read the FDA’s announcement here.
Download the List of Affected Products
Infant Formula Recalled after Reports of Botulism
Three Infants Hospitalized; Nationwide Recall Initiated Nara Organics has voluntarily recalled all lots of its powdered infant formula currently on the U.S. market following reports of three cases of infant botulism in infants who reportedly consumed the product. ...
FDA Clears First OTC Continuous Glucose Monitor for Children
Regulatory Snapshot Device: Stelo® Glucose Biosensor System (Dexcom, Inc.)Indication: Continuous glucose monitoring for individuals ages 2 years and older who do not use insulin, including children with diabetes managed through oral medications and individuals seeking...
FDA Early Alert for Baxter Pressure Breathing Device
FDA Issues Early Alert for Baxter Volara System Patient Circuits Following Therapy Leakage Concerns The U.S. Food and Drug Administration (FDA) has issued an Early Alert regarding a potentially high-risk issue affecting certain Baxter Volara System patient circuits...
FDA Early Alert – Hamilton Medical Breathing Circuit Sets
FDA Issues Early Alert for Hamilton Medical Breathing Circuit Sets Following Reports of Serious Injuries The U.S. Food and Drug Administration (FDA) has issued an Early Alert regarding certain Hamilton Medical coaxial breathing circuit sets used with HAMILTON-C1,...
FDA Early Alert for GE HealthCare Infant Resuscitation Systems
FDA Issues Early Alert for GE HealthCare Infant Resuscitation Systems Due to Oxygen Blender Issue Early Alert for GE HealthCare Infant Resuscitation Systems The U.S. Food and Drug Administration (FDA) has issued an Early Alert regarding a potentially high-risk issue...
FDA-Approved Vivistim: A New Pathway in Stroke Recovery
Vivistim implantable vagus nerve stimulator. Source: Vivistim.com.FDA-Approved Vagus Nerve Stimulation Device Opens a New Pathway in Stroke Recovery A company behind one of the world’s most closely watched neurorehabilitation technologies is preparing for a major new...